Bergen, Norway, 11 August 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, will announce its results for the second quarter and half year 2017 on Friday, 18 August 2017.
A presentation by BerGenBio’s senior management team will take place at 10.00 am CET at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo
Meeting Room: Bjørvika
The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Reports and presentations/Webcasts. A recording will be available shortly after the webcast has finished.
The results report and the presentation will be available at www.bergenbio.com in the section: Investors/Reports and presentations from 7:00 am CET the same day.
-Ends-
Contacts
Richard Godfrey
CEO, BerGenBio ASA
media@bergenbio.com
+47 917 86 304
David Dible, Mark Swallow, Marine Perrier
Citigate Dewe Rogerson
bergenbio@citigatedr.co.uk?
+44 207 638 9571
